Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.68 |
| ▸ | RORC | P51449 | 18/20 | 0.69 |
| ▸ | RARG | P13631 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17184051 | 0.91 | RORC (0.80) | RORCPPARGRARG | |
| SCHEMBL12470473 | 0.90 | RORC (0.85) | RORCPPARG | |
| SCHEMBL17184039 | 0.90 | RORC (0.79) | RORCPPARGRARG | |
| SCHEMBL12470433 | 0.87 | RORC (0.81) | RORCPPARGRARG | |
| SCHEMBL12470388 | 0.84 | RORC (0.84) | RORCPPARG | |
| SCHEMBL12470587 | 0.83 | RORC (0.67) | RORCPPARGCYP3A4 | |
| SCHEMBL12471089 | 0.82 | RORC (0.73) | RORCPPARGRARG | |
| SCHEMBL12470407 | 0.82 | RORC (1.00) | RORCPPARG | |
| SCHEMBL12470471 | 0.81 | RORC (0.98) | RORCPPARG | |
| SCHEMBL11903924 | 0.81 | RORC (1.00) | RORCPPARGRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2683693-B1 | RORGAMMAT INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | claimed |
| US-9603838-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-28 | — | — | US | claimed |
| US-20150297566-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME LLC | 2015-10-22 | — | — | US | claimed |
| US-20140038942-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-02-06 | — | — | US | claimed |
| EP-2683693-A1 | RORGAMMAT INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-01-15 | — | — | EP | claimed |
| WO-2012106995-A1 | RORGAMMAT INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-08-16 | — | — | WO | claimed |
| US-9884043-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170340610-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME LLC | 2017-11-30 | — | — | US | disclosed |
| EP-2683693-B1 | RORGAMMAT INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9603838-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150297566-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME LLC | 2015-10-22 | — | — | US | disclosed |
| US-9095583-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140038942-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-02-06 | — | — | US | disclosed |
| EP-2683693-A1 | RORGAMMAT INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-01-15 | — | — | EP | disclosed |
| WO-2012106995-A1 | RORGAMMAT INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297566-A1 | RORgammaT INHIBITORS | RORB, RORC, RORA | PPARG 90/4885RORC 2/4885RARG 17/4885 |
| US-20170340610-A1 | RORgammaT INHIBITORS | RORB, RORC, RORA | PPARG 103/4885RORC 2/4885RARG 12/4885 |
| US-20140038942-A1 | RORgammaT INHIBITORS | RORB, RORC, RORA | PPARG 103/4885RORC 2/4885RARG 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.